OMEROS CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $OMER in the last 7 days.
Omeros (OMER) +13%, Alpha Teknova (TKNO) +5%, BioLife (BLFS) +6%, Schrodinger (SDGR) +4%, and InfuSystem (INFU) +2% hit 52-week highs. OMER reported $32.2M Q2 sales for YARTEMIS. TKNO launched Fill-Tek, with Q2 revenue up 18%. BLFS to be acquired by Repligen (RGEN) for $1.5B, Q2 revenue up 21%. SDGR co-founded Tectora. INFU Q2 revenue $36.9M, up 2.6%.
Natera (NTRA) and Omeros (OMER) shares rose on Tuesday, with NTRA hitting an all-time high and OMER reaching a 5-year peak. NTRA's cancer test received Japanese regulatory approval, while OMER was upgraded by Cantor Fitzgerald due to optimism about its lead drug's potential. NTRA is up 5%, OMER up 12% at the time of writing.
Omeros Corporation (OMER) shares rose 5% after hours on optimism about its deal with Novo Nordisk and drug launches. Q4 net income was $86.5M, up from a $31.4M loss in 2024, including a $237.6M gain from the zaltenibart transaction. The company expects milestone payments and royalties from Novo Nordisk and anticipates positive cash flow by 2027.
Recent OMER coverage spans earnings, insider activity and market movers.
In the last 30 days, OMER insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($419K). The most active reporter was Borges David J., VP, Finance & CAO, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive price momentum may attract short‑term buyers.
Analyst upgrade with a higher peak sales thesis can extend the stock’s momentum and improve risk appetite around Yartemlea commercialization.
Positive earnings and a large cash infusion improve near‑term liquidity and support upside.
The insider sale may signal reduced confidence or liquidity needs, potentially pressuring the stock short-term.
Insider sale by a director may signal weak confidence, potentially pressuring the stock.
AlphAI scores every news story that mentions OMER with an AI model for sentiment and relevance, and aggregates insider trades from OMEROS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Omeros (OMER) +13%, Alpha Teknova (TKNO) +5%, BioLife (BLFS) +6%, Schrodinger (SDGR) +4%, and InfuSystem (INFU) +2% hit 52-week highs. OMER reported $32.2M Q2 sales for YARTEMIS. TKNO launched Fill-Tek, with Q2 revenue up 18%. BLFS to be acquired by Repligen (RGEN) for $1.5B, Q2 revenue up 21%. SDGR co-founded Tectora. INFU Q2 revenue $36.9M, up 2.6%.
2 min readNatera (NTRA) and Omeros (OMER) shares rose on Tuesday, with NTRA hitting an all-time high and OMER reaching a 5-year peak. NTRA's cancer test received Japanese regulatory approval, while OMER was upgraded by Cantor Fitzgerald due to optimism about its lead drug's potential. NTRA is up 5%, OMER up 12% at the time of writing.
5 min readOmeros Corporation (OMER) shares rose 5% after hours on optimism about its deal with Novo Nordisk and drug launches. Q4 net income was $86.5M, up from a $31.4M loss in 2024, including a $237.6M gain from the zaltenibart transaction. The company expects milestone payments and royalties from Novo Nordisk and anticipates positive cash flow by 2027.
2 min readCancelmo Peter B (VP, General Counsel) sold 50,000 shares of OMEROS CORP (OMER) at an average of $18.59 ($18.54–$18.65, $0.93M total) across 2 trades over 2026-08-28 to 2026-08-31.
1 min readHANISH ARNOLD C sold 15,000 shares of OMEROS CORP (OMER) at an average of $18.81 ($18.53–$19.02, $0.28M total) across 3 trades over 2026-08-26 to 2026-08-27.
1 min readOmeros Corp's (NASDAQ:OMER) VP of Finance, David Borges, sold 10,906 shares for $206,804 after exercising options. Shares were sold at $18.95-$19.10, with options exercised at $2.94-$3.93. Omeros reported Q2 earnings of $0.02 per share, beating estimates, and revenue of $28.5M, also exceeding forecasts, driven by its drug YARTEMLEA.
2 min readCable Thomas J. sold 15,000 shares of OMEROS CORP (OMER) at $18.45 ($0.28M total) on 2026-08-20.
1 min readOmeros (OMER) reported Q2 2026 earnings with Yartemlia gross sales at $32.2M, up 190% from Q1. Net income was $13.2M, including a $11.5M non-cash gain. The company reduced debt by 43% and generated $4.1M in operating cash flow. However, the EMA's committee issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA.
3 min readOmeros (OMER) reported Q2 2026 results moving from net losses to net income of $13.23M, and half-year net income of $69.29M. The company also completed a buyback of 843,187 shares for $9.87M under its Dec 2025 program and expanded its board to nine, adding Joseph Schocken. The article cites an ESOP-related $142.67M shelf registration and forecasts to 2029.
6 min readOmeros reported Q2 2026 progress for Yartemlia, citing 188% quarter-over-quarter net sales growth and $4.1 million positive operating cash flow. Management said adult transplant centers now drive about 75% of sales and formulary approval is 55% to 60%. It also discussed cash flow positivity by mid-2027, repurchases, and regulatory items including a July 1 J-code and Oct. 1 NTAP.
5 min read
